Merck News (NYSE:MRK)

DateTimeSource
Headline
03/22/20174:05PMBWMerck Animal Health Completes Acquisition of Vallée S.A.
Broadening Our Comprehensive Portfolio of Animal Health Products for Brazilian Market Merck Animal Health (known as MSD Animal Health outside the United States and Canada) today announced it has successfully acquired a controlling interest in Vallée S.A., a leading privately-held producer of animal health products in... More...>>
03/14/20175:05PMBWFDA Approves Merck’s KEYTRUDA® (pembrolizumab) for Adult & Pediatric Patients with Classical Hodgkin Lymphoma (cHL) Refrac...
Only Anti-PD-1 Therapy Approved for the Treatment of Patients with Difficult-to-Treat cHL Regardless of Prior Stem Cell Transplantation or Use of Brentuximab Vedotin Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA®... More...>>
03/14/20174:43PMBWMerck Provides Update on Supplemental Biologics License Application (sBLA) for KEYTRUDA® (pembrolizumab) in Previously Treat...
Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has extended the action date for the supplemental Biologics License Application (sBLA) for KEYTRUDA® (pembrolizumab), the company’s anti-PD-1 therapy, for previously treated patients... More...>>
03/10/20175:32AMPRNCANew Merck Technology Aims to Further Optimize Embryo Incubation and Assessment
New Merck Technology Aims to Further Optimize Embryo Incubation and Assessment Canada NewsWire DARMSTADT, Germany, March 10, 2017 DARMSTADT, Germany, March 10, 2017 /CNW/ - Merck integrates innovative Eeva® Test with Geri™ incubation platform, bringing individualized incubation and outcome prediction together  Geri™... More...>>
03/06/20179:47AMDJNRace Tightens for Next Wave of Cancer Drugs
By Peter Loftus WILMINGTON, Del. -- In the race to develop the next wave of drugs that use the immune system to fight cancer, scientists scurry up and down escalators in an old department store here. Their biotechnology company, Incyte Corp., set up shop in a former John Wanamaker store on the outskirts of Wilmington in... More...>>
03/06/20178:00AMBWMerck & Pfizer Announce U.S. FDA & EMA Filing Acceptances of Three Marketing Applications for Ertugliflozin-Containing Medici...
Investigational SGLT2 Inhibitor Submitted as Monotherapy and in Fixed-Dose Combinations with JANUVIA® (sitagliptin) or Metformin Merck (NYSE:MRK), known as MSD outside the United States and Canada, and Pfizer Inc. (NYSE:FE), today announced that the U.S. Food and Drug Administration (FDA) has accepted for review three... More...>>
02/28/20171:47PMBWMerck Announces Second-Quarter 2017 Dividend
Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the Board of Directors has declared a quarterly dividend of $0.47 per share of the company’s common stock for the second quarter of 2017. Payment will be made on April 7, 2017 to shareholders of record at the close of business... More...>>
02/28/20171:00PMBWRecent Survey Finds Many Adults with Diabetes Unaware of Their Increased Risk for Certain Serious Illnesses
Findings Reinforce the Need for Greater Discussions Between Health Care Professionals and Patients to Help Them Understand Their Increased Risk For Pneumococcal Pneumonia/Pneumococcal Disease, Flu and Hepatitis B Many adults with diabetes are unaware of their increased risk for certain serious illnesses, including pneumococcal... More...>>
02/26/201712:30PMBWMerck’s Letermovir, an Investigational Antiviral Medicine for Prevention of Cytomegalovirus (CMV) Infection in Bone Marrow ...
Letermovir Prophylaxis Associated with Lower All-Cause Mortality Through Week 24 Post-Transplant Company Plans to Submit New Drug Applications for Letermovir in U.S. and EU in 2017 Merck & Co., Inc. (NYSE:MRK), known as MSD outside the United States and Canada, today announced results of the pivotal Phase 3 clinical... More...>>
02/24/20174:00PMBWIn First Phase 3 Trial, Merck’s Investigational Inactivated Varicella Zoster Virus Vaccine (V212) Reduced the Incidence of ...
Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the first Phase 3 study results for V212, the company’s investigational inactivated varicella zoster virus vaccine (VZV) for the prevention of herpes zoster or HZ, also known as shingles, in immunocompromised patients. This was a double-blind... More...>>
02/24/20178:32AMPRNCAMerck Receives Positive CHMP Opinion for New Pergoveris® Fertility Pen
Merck Receives Positive CHMP Opinion for New Pergoveris® Fertility Pen Canada NewsWire DARMSTADT, Germany, Feb. 24, 2017 Not intended for U.S. and UK based media  Ready-to-use pre-filled pen provides a convenient treatment option for patients  Simplified injection device for self-administration comes... More...>>
02/16/20178:00AMBWMerck’s Fight Against Infectious Disease Goes Digital with Launch of ILÚM Health Solutions
Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the launch of ILÚM Health Solutions, which provides enterprise-wide disease management tools and services to enable improved outcomes for patients with infectious diseases, such as sepsis and pneumonia, while supporting antimicrobial... More...>>
02/14/20177:06PMDJNMerck Stops Clinical Trial of Alzheimer's Drug
By Peter Loftus Merck & Co. said Tuesday it stopped a clinical trial of an experimental Alzheimer's drug because it wasn't helping patients, the latest setback in the pharmaceutical industry's quest to find a better treatment for the brain disorder. An outside committee monitoring the study of more than... More...>>
02/14/20175:00PMBWMerck Announces EPOCH Study of Verubecestat for the Treatment of People with Mild to Moderate Alzheimer’s Disease to Stop f...
APECS Study in People with Prodromal Alzheimer’s Disease to Continue Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that it will be stopping protocol 017, also known as the EPOCH study, a Phase 2/3 study evaluating verubecestat, an investigational small molecule inhibitor of the... More...>>
02/14/20174:05PMBWMerck’s Doravirine, an Investigational Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) for the Treatment of HIV-1 In...
Data Presented at CROI Showed Doravirine Was Non-inferior to Ritonavir-boosted Darunavir in Treatment-naïve Adults after 48 weeks of Treatment Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced results of a pivotal Phase 3 clinical trial evaluating the safety and efficacy of doravirine... More...>>
02/11/20173:02AMDJNReckitt Agrees to Mead Deal -- WSJ
By Saabira Chaudhuri LONDON -- Reckitt Benckiser Group PLC on Friday said it agreed to buy baby-food maker Mead Johnson Nutrition Co. for $16.6 billion, a deal that will almost double the size of the British company's consumer-health business and push it deeper into emerging markets. Reckitt, whose lineup includes... More...>>
02/10/20178:22AMDJNReckitt Benckiser to Buy Mead Johnson for $16.6 Billion -- 4th Update
By Saabira Chaudhuri LONDON-- Reckitt Benckiser Group PLC on Friday said it agreed to buy baby-food maker Mead Johnson Nutrition Co. for $16.6 billion, a deal that will almost double the size of the British company's consumer-health business and help it push deeper into emerging markets. The U.K. company, which owns... More...>>
02/10/20176:25AMDJNReckitt Benckiser to Buy Mead Johnson for $16.6 Billion -- 3rd Update
By Saabira Chaudhuri LONDON-- Reckitt Benckiser Group PLC on Friday said it agreed to buy baby-food maker Mead Johnson Nutrition Co. for $16.6 billion, a deal that will almost double the size of the British company's consumer-health business and help it push deeper into emerging markets. The U.K. company, which owns... More...>>
02/10/20174:21AMDJNReckitt Benckiser to Buy Mead Johnson for $16.6 Billion -- 2nd Update
By Saabira Chaudhuri LONDON-- Reckitt Benckiser Group PLC on Friday said it agreed to buy baby-food maker Mead Johnson Nutrition Co. for $16.6 billion, a deal that will almost double the size of the British company's consumer-health business and help it push deeper into emerging markets. The U.K. company, which owns... More...>>
02/09/20179:00AMBWMerck Foundation Announces Six Program Grant Recipients for Alliance to Advance Patient-Centered Cancer Care
Alliance Aims to Reduce Disparities in Access to High-Quality Cancer Care The Merck Foundation (Foundation), announced today the selection of the six program sites and National Program Office forming the Alliance to Advance Patient-Centered Cancer Care (the Alliance). With $15 million in funding from the Foundation over... More...>>
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:43 V:us D:20170324 08:10:46